🌍August 20, 2026·Aug 20discovery

【Kringle Pharma FY2026 Q3 Earnings Call】Phase 3 Additional Trial for Spinal Cord Injury Begins, Basic Agreement with Maruishi Pharmaceutical for Vocal Fold Fibrosis Sales, Full-Year Revenue ¥323 Million

Publisher

finance.biggo.com

Global

This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: finance.biggo.com
Region: Global
Scope: discovery
Published: August 20, 2026
Language: EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on news.google.com

Leave the platform to read the original full article on the publisher site.

Source: finance.biggo.com

Scope: discovery

Open original article

Related coverage

More related coverage

eu.36kr.com/4h ago

AI Drug Discovery: On the Eve of Full Value Realization in Modern Pharmaceutical Innovation

MarketScale/4h ago

Clinical data harmonization is the bottleneck for life sciences AI

Maryland Matters/4h ago

Commentary: The Prescription Drug Affordability Board is working, it's time to press forward, not back

Stock Titan/4h ago

【Kringle Pharma FY2026 Q3 Earnings Call】Phase 3 Additional Trial for Spinal Cord Injury Begins, Basic Agreement with Maruishi Pharmaceutical for Vocal Fold Fibrosis Sales, Full-Year Revenue ¥323 Million

More related coverage

AI Drug Discovery: On the Eve of Full Value Realization in Modern Pharmaceutical Innovation

Clinical data harmonization is the bottleneck for life sciences AI

Commentary: The Prescription Drug Affordability Board is working, it's time to press forward, not back

Results are due Monday from a study of two potential treatments for an age-related eye disease.